JMKX000189
/ Shanghai Jeyou Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 10, 2024
A multicenter, randomized, double-blind, placebo-controlled phase II/III clinical study to evaluate the efficacy and safety of JMKX000189 tablets in inducing and maintaining treatment of moderate to severe active ulcerative colitis
(ChiCTR)
- P2/3 | N=677 | Recruiting | Sponsor: The First Affiliated Hospital of Sun Yat sen University; Shanghai Jiyu Pharmaceutical Co., LTD
New P2/3 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP
August 01, 2023
JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus
(clinicaltrials.gov)
- P2a | N=48 | Recruiting | Sponsor: Jemincare
New P2a trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
1 to 2
Of
2
Go to page
1